title: Intraoperative fluorescence-guided resection of high-grade malignant gliomas using 5-aminolevulinic acid-induced porphyrins: a systematic review and meta-analysis of prospective studies.
abstract: BACKGROUND
  We performed a systematic review and meta-analysis to address the (added) value of intraoperative 5-aminolevulinic acid (5-ALA)-guided resection of high-grade malignant gliomas compared with conventional neuronavigation-guided resection, with respect to diagnostic accuracy, extent of tumor resection, safety, and survival.
  
  
  RESULTS
  An electronic database search of Medline, Embase, and the Cochrane Library was undertaken. The review process followed the guidelines of the Cochrane Collaboration. 10 studies matched all selection criteria, and were thus used for qualitative synthesis. 5-ALA-guided resection demonstrated an overall sensitivity of 0.87 (95% confidence interval [CI], 0.81-0.92), specificity of 0.89 (95% CI, 0.79-0.94), positive likelihood ratio (LR) of 7.62 (95% CI, 3.87-15.01), negative LR of 0.14 (95% CI, 0.09-0.23), and diagnostic odds ratio (OR) of 53.06 (95% CI, 18.70-150.51). Summary receiver operating characteristic curves (SROC) showed an area under curve (AUC) of 94%. Contrast-enhancing tumor was completely resected in patients assigned 5-ALA as compared with patients assigned white light. Patients in the 5-ALA group had higher 6-month progression free survival and overall survival than those in the white light group.
  
  
  CONCLUSIONS
  Based on available literature, there is level 2 evidence that 5-ALA-guided surgery is more effective than conventional neuronavigation-guided surgery in increasing diagnostic accuracy and extent of tumor resection, enhancing quality of life, or prolonging survival in patients with high-grade malignant gliomas.
authors.affiliation: Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China. guangsz@hotmail.com
authors.forename: Shiguang
authors.initials: S
authors.lastname: Zhao
authors.forename: Jianing
authors.initials: J
authors.lastname: Wu
authors.forename: Chunlei
authors.initials: C
authors.lastname: Wang
authors.forename: Huailei
authors.initials: H
authors.lastname: Liu
authors.forename: Xingli
authors.initials: X
authors.lastname: Dong
authors.forename: Chen
authors.initials: C
authors.lastname: Shi
authors.forename: Changbin
authors.initials: C
authors.lastname: Shi
authors.forename: Yaohua
authors.initials: Y
authors.lastname: Liu
authors.forename: Lei
authors.initials: L
authors.lastname: Teng
authors.forename: Dayong
authors.initials: D
authors.lastname: Han
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: Chen
authors.forename: Guang
authors.initials: G
authors.lastname: Yang
authors.forename: Ligang
authors.initials: L
authors.lastname: Wang
authors.forename: Chen
authors.initials: C
authors.lastname: Shen
authors.forename: Huadong
authors.initials: H
authors.lastname: Li
mesh_terms: D000622:Aminolevulinic Acid / Q000008:administration & dosage / Q000009:adverse effects; D001932:Brain Neoplasms / Q000175:diagnosis / Q000601:surgery*; D002986:Clinical Trials as Topic; D005453:Fluorescence; D005910:Glioma / Q000175:diagnosis / Q000601:surgery*; D006801:Humans; D007430:Intraoperative Care; D038361:Neuronavigation; D011166:Porphyrins; D011446:Prospective Studies; D012372:ROC Curve; D012680:Sensitivity and Specificity; D016019:Survival Analysis
chemical_list: D011166:Porphyrins; D000622:Aminolevulinic Acid